Skip to content

Research paper

Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial.

The British journal of nutrition
Q1
Jul 2008
Citations: 44
Influential: 6
Interventional (Human) Studies
90

Study answer

What this study found

The NOPE-EGCG formula improved adherence to the prescribed diet and several related outcomes versus placebo, but it did not produce significantly greater weight loss over 8 weeks. Compliance with the diet was achieved by 67 (94%) in the NOPE-EGCG group versus 49 (73%) in placebo (P=0.001), and dropout was 6% versus 27% (P=0.001). The supplement also improved insulin resistance (P<0.001), fullness/satiety (P=0.05), depressive symptoms on the Beck Inventory Scale (mean change -4.21 vs -1.36; treatment effect -2.85, 95% CI -4.78 to 0.91; P=0.005), and binge eating severity on the Binge Eating…

Study & population
Randomized controlled trial in healthy overweight adults of both sexes in Italy.
Intervention
The active supplement was PhosphoLEANe, taken orally as one capsule twice daily before lunch and dinner for 8 weeks, alongside a prescribed low-energy diet.
Key limitation
The intervention was tested over only 8 weeks, so durability of effects and longer-term weight outcomes remain uncertain.
View sourceOpen PDF

Original abstract

Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of admini…